Stoke Therapeutics (STOK) Consolidated Net Income: 2022-2025
Historic Consolidated Net Income for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$38.3 million.
- Stoke Therapeutics' Consolidated Net Income fell 45.09% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 138.26%. This contributed to the annual value of -$88.7 million for FY2024, which is 15.38% up from last year.
- According to the latest figures from Q3 2025, Stoke Therapeutics' Consolidated Net Income is -$38.3 million, which was down 63.30% from -$23.5 million recorded in Q2 2025.
- Stoke Therapeutics' Consolidated Net Income's 5-year high stood at $112.9 million during Q1 2025, with a 5-year trough of -$38.3 million in Q3 2025.
- Its 3-year average for Consolidated Net Income is -$13.0 million, with a median of -$25.7 million in 2024.
- Examining YoY changes over the last 5 years, Stoke Therapeutics' Consolidated Net Income showed a top increase of 527.99% in 2025 and a maximum decrease of 45.09% in 2025.
- Stoke Therapeutics' Consolidated Net Income (Quarterly) stood at -$25.7 million in 2022, then decreased by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then tumbled by 45.09% to -$38.3 million in 2025.
- Its last three reported values are -$38.3 million in Q3 2025, -$23.5 million for Q2 2025, and $112.9 million during Q1 2025.